B7-H3 CAR-DC

B7-H3 CAR-DC is a first-in-class chimeric antigen receptor dendritic cell (CAR-DC) therapy designed to treat solid and liquid tumors. Developed by researchers at Washington University School of Medicine, this platform utilizes type I conventional dendritic cells (cDCs) engineered with a non-integrating mRNA-encoded CAR specific for B7-H3 (CD276). Unlike CAR-T cells, which act as direct effectors, CAR-DCs function as potent antigen-presenting cells. Upon binding B7-H3-expressing tumor cells, the CAR-DCs enhance the uptake of diverse tumor antigens, undergo maturation, and cross-present these antigens to endogenous CD8+ T cells. This process drives a broad, polyclonal antitumor immune response that extends beyond the CAR-restricted epitope, potentially overcoming tumor heterogeneity and antigen escape. Preclinical studies in sarcoma models have demonstrated that both intratumoral and intravenous administration can induce complete tumor regression and establish durable immunological memory.

Other names

B7-H3-targeted chimeric antigen receptor dendritic cellsB-7-H3-targeted chimeric antigen receptor dendritic cellsB 7-H3-targeted chimeric antigen receptor dendritic cells